Document is current
Any future updates will be listed below
-
Authors
Coral, Daniel E. https://orcid.org/0000-0002-8809-4544
Fernandez-Tajes, Juan
Tsereteli, Neli
Pomares-Millan, Hugo https://orcid.org/0000-0001-9245-4576
Fitipaldi, Hugo https://orcid.org/0000-0001-5352-2134
Mutie, Pascal M.
Atabaki-Pasdar, Naeimeh https://orcid.org/0000-0001-7229-1888
Kalamajski, Sebastian
Poveda, Alaitz
Miller-Fleming, Tyne W.
Zhong, Xue
Giordano, Giuseppe N. https://orcid.org/0000-0002-6719-6680
Pearson, Ewan R. https://orcid.org/0000-0001-9237-8585
Cox, Nancy J.
Franks, Paul W. https://orcid.org/0000-0002-0520-7604
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (875534, 875534, 875534, 875534)
- License Information
-
More Information
Article History
Received: 14 December 2021
Accepted: 20 December 2022
First Online: 26 January 2023
Ethics statements
: Ethics approval for the UK Biobank was obtained from the North West Centre for Research Ethics Committee. Analysis of individual-level data from UK Biobank participants in Lund University was approved by the Swedish Ethical Review Authority (2021-0317). The BioVU project was approved by the VUMC Institutional Review Board. The analysis of individual-level data was performed in VUMC, and only summary results were shared with researchers at Lund University. Both studies conformed to the ethical principles for medical research involving human participants outlined in the Declaration of Helsinki. All participants provided written informed consent at enrolment.
: All collaborators of this study have fulfilled the criteria for authorship required by Nature Portfolio journals have been included as authors, as their participation was essential for the design and implementation of the study. Roles and responsibilities were agreed among collaborators ahead of the research. This work includes findings that are locally relevant, which have been determined in collaboration with local partners. This research was not severely restricted or prohibited in the setting of the researchers, and does not result in stigmatization, incrimination, discrimination or personal risk to participants. Local and regional research relevant to our study was taken into account in citations.
: P.W.F. has received research grants from numerous diabetes drug companies and fees as consultant from Novo Nordisk, Lilly and Zoe. He is currently the Head of the Department of Translational Medicine at the Novo Nordisk Foundation. All other authors declare non-competing interests.
